Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Expected to Post Earnings of -$0.24 Per Share

Equities research analysts predict that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will post earnings per share of ($0.24) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.14). Pieris Pharmaceuticals posted earnings of ($0.26) per share in the same quarter last year, which indicates a positive year over year growth rate of 7.7%. The business is expected to report its next quarterly earnings results on Wednesday, November 3rd.

On average, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.78) per share for the current year, with EPS estimates ranging from ($1.05) to ($0.49). For the next year, analysts expect that the firm will report earnings of ($0.79) per share, with EPS estimates ranging from ($1.10) to ($0.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, August 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.05). The company had revenue of $3.29 million during the quarter, compared to analyst estimates of $8.53 million. Pieris Pharmaceuticals had a negative net margin of 205.63% and a negative return on equity of 122.26%.

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group upped their price objective on shares of Pieris Pharmaceuticals from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, June 30th. Zacks Investment Research cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 10th. Finally, William Blair restated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Friday, July 2nd.

In other Pieris Pharmaceuticals news, insider Shane Olwill sold 38,400 shares of the company’s stock in a transaction on Monday, August 30th. The stock was sold at an average price of $5.11, for a total value of $196,224.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.77% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in Pieris Pharmaceuticals during the second quarter valued at $11,309,000. Point72 Asset Management L.P. bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $3,830,000. Morgan Stanley boosted its holdings in shares of Pieris Pharmaceuticals by 104.6% in the 2nd quarter. Morgan Stanley now owns 1,675,969 shares of the biotechnology company’s stock worth $6,419,000 after acquiring an additional 856,793 shares in the last quarter. EAM Investors LLC acquired a new position in Pieris Pharmaceuticals during the 2nd quarter worth $1,105,000. Finally, Ergoteles LLC acquired a new position in Pieris Pharmaceuticals during the 2nd quarter worth $796,000. Institutional investors and hedge funds own 39.92% of the company’s stock.

Shares of NASDAQ PIRS traded down $0.34 during midday trading on Thursday, reaching $5.43. 30,885 shares of the company were exchanged, compared to its average volume of 4,390,845. The stock has a market cap of $362.24 million, a P/E ratio of -6.87 and a beta of 1.19. The stock’s 50-day moving average price is $4.50 and its 200-day moving average price is $3.43. Pieris Pharmaceuticals has a one year low of $1.70 and a one year high of $6.15.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Featured Article: Equal Weight Rating

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.